Healthcare Industry News:  King Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - April 18, 2006

Exaeris, Unit Of Inyx, Announces Key Appointments

Two New Board of Directors Additions of Director of Marketing and District Manager

EXTON, Pa., April 18 (HSMN NewsFeed) -- Exaeris, Inc., a wholly owned subsidiary of Inyx, Inc. (OTC Bulletin Board: IYXI ), announced today that it has appointed two non-executive members to its Board of Directors: Bruce Simpson, an accomplished pharmaceutical executive, and William Storms, M.D., a recognized key opinion leader in respiratory medicine. Exaeris also announced two recent management hires: Christopher Henshall has joined the company in the newly established position of Director of Marketing, and Steven Surrette in the position of East Regional District Manager.

"Bruce Simpson and Bill Storms expand the leadership on the Exaeris board, ensuring strong corporate governance and strategic insight from both corporate and customer perspectives. This will enable us to better execute sound business initiatives that are relevant to industry needs," said Stephen Beckman, President of Exaeris.

Bruce Simpson is currently principal of Bruce Simpson and Associates, a strategic consulting and business development firm. Prior to forming his own firm, Mr. Simpson held numerous leadership positions, including serving as president of Genpharm, Inc. and Medeva Pharmaceuticals, Inc. He has over 20 years of experience in the respiratory and primary care fields, and he has a proven track record as a business development expert. "I am excited to be a part of this endeavor, Exaeris and Inyx are establishing themselves as an important player in the global development, manufacturing, and commercial promotion of respiratory and primary care products," said Mr. Simpson.

William Storms M.D. is a highly accomplished allergist, board certified in internal medicine, and allergy and immunology. Dr. Storms is a practicing allergist in Colorado Springs, CO, Clinical Professor of Medicine, University of Colorado, member of the Sports Medicine Committee of the U.S. Olympic Committee since 1997, and the co-chair of the Professional and Patient/Public Education subcommittee of the National Asthma Education Prevention Program (NAEPP). In addition, Dr. Storms, a distinguished international speaker, has overseen hundreds of clinical drug trials and published over 65 articles.

"Dr. Storms brings a comprehensive knowledge of the customer base combined with a strong ability to translate this into effective clinical trial and business acumen," said Mr. Beckman. Included in his experience is a strong working knowledge of Intal® (cromolyn sodium), the lead respiratory product for King Pharmaceuticals, Inc. (NYSE: KG ) that is promoted by Exaeris. "Exaeris can play an important role in supporting physicians' ability to improve the therapeutic outcomes for patients suffering from a range of respiratory disorders. I am impressed with the competency and dedication this company has demonstrated in a short time and look forward to representing the customer perspective," said Dr. Storms.

The Exaeris board is now comprised of two executive and two non-executive members and will work aggressively to leverage the vertically integrated business platform of Inyx, Mr. Beckman added.

Exaeris also announced that Christopher Henshall recently joined the company as Director of Marketing. Mr. Henshall brings both international and domestic marketing experience in the respiratory and gastrointestinal sectors. Mr. Henshall has led a number of global and regional brands, developed many highly successful marketing programs with Altana Pharmaceuticals and managed important industry partnerships with companies such as Pfizer.

Steven Surrette has joined Exaeris in the position of East Regional District Manager. Mr. Surrette has extensive sales management experience and served previously with Merz, Romark and Forest Laboratories.

Intal® and Tilade®

Intal® and Tilade® are mast-cell stabilizers (non-steroidal anti- inflammatory, non-beta-2 agonist agents) for the treatment of asthma. Intal® is administered with either an inhaler or a nebulizer and is indicated for the long-term treatment of bronchial asthma in adults and children five years of age and older. Tilade® is administered with an inhaler and is indicated for the long-term treatment of bronchial asthma and associated chronic cough in adults. A new Intal® inhaler formulation utilizing hydrofluoroalkane ("HFA"), an environmentally friendly propellant, is currently under review by the U.S. Food and Drug Administration ("FDA"). The HFA formulation of Intal® is patented in the United States until September 2017.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions. Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services. In addition, Inyx is developing its own proprietary products. The company's operations are conducted through several wholly owned subsidiaries, including: Inyx USA, Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd., and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; and Inyx Canada, Inc. in Toronto. Inyx, Inc.'s corporate offices are in New York City. For more information, please visit:

About Exaeris, Inc.

Exaeris, Inc., located in Exton, PA, is a wholly owned subsidiary of Inyx, Inc. Exaeris, which is Inyx's new marketing arm, seeks to market a range of respiratory and other pharmaceutical products acquired or in collaboration with strategic industry partners as well as Inyx's own proprietary products.

Safe Harbor

Statements about Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results.

Source: Exaeris

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.